Hypolipidaemic properties of a potent and bioavailable alkylsulphinyl-diphenylimidazole ACAT inhibitor (RP 73163) in animals fed diets low in cholesterol

Biochemical Pharmacology

Volumn 52, Issue 8, 1996, Pages 1177-1186

  Riddell, David ^a   Bright, Colin P ^a   Burton, Brenda J ^a   Bush, Raymond C ^a   Harris, Neil V ^a   Hele, David ^a   Moore, Una M ^a   Naik, Kuni ^a   Parrott, David P ^a   Smith, Christopher ^a   Williams, Robert J ^a  

^a Dagenham Research Centre   (United Kingdom)

Author keywords

acyl CoA:cholesterol acyltransferase; apoB; cholesterol; fasting; plasma lipoproteins; VLDL secretion

Indexed keywords

2 [5 (3,5 DIMETHYL 1 PYRAZOLYL)PENTYLSULFINYL] 4,5 DIPHENYLIMIDAZOLE; 2,2 DIMETHYL N (2,4,6 TRIMETHOXYPHENYL)DODECANAMIDE; 3 (2,4 DIFLUOROPHENYL) 1 HEPTYL 1 (4 NEOPENTYLBENZYL)UREA; ANTILIPEMIC AGENT; APOLIPOPROTEIN B; CASEIN; CHOLESTEROL; CHOLESTEROL ACYLTRANSFERASE; CHOLESTEROL ACYLTRANSFERASE INHIBITOR; LEUCINE; LIPID; LOW DENSITY LIPOPROTEIN; RADIOISOTOPE; TRIACYLGLYCEROL; TYLOXAPOL; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL LINE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DIET; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG POTENCY; ENZYME INHIBITION; HUMAN; HUMAN CELL; HYPERCHOLESTEROLEMIA; INTESTINE; INTRAGASTRIC DRUG ADMINISTRATION; LIPID BLOOD LEVEL; LIPID METABOLISM; LIVER; MALE; MICROSOME; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RABBIT; RAT; SYRIAN HAMSTER;

EID: 0030601892     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/0006-2952(96)00455-8     Document Type: Article

References (43)

1. 1. Zemel PC and Sowers JR, Relation between lipids and atherosclerosis: epidemiologic evidence and clinical implications. Am J Cardiol 66: 71-121, 1990.
2. 2. Lipid Research Clinics Program, The Lipid Research Clinics Coronary Primary Prevention Trial Results II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA 251: 365-374, 1984.
3. 3. Mack WJ, Hodis HN and Blankenhorn DH, Regression of atherosclerosis: a report from two clinical trials. In: Atherosclerosis Reviews (Eds. Weber PC and Leaf A), Vol. 25, pp. 301-309. Raven Press, New York, 1993.
4. 4. Kesaniemi YA and Miettinen TA, Cholesterol absorption efficiency regulates plasma cholesterol level in the Finnish population. Eur J Clin Invest 17: 391-395, 1987.
5. 5. Sniderman A, Brown BG, Stewart BF and Cianflone K, From familial combined hyperlipidemia to hyperapoB: unravelling the over production of hepatic apolipoprotein B. Curr Opin Lipidol 3: 137-142, 1992.
6. 6. Bennett Clark S and Tercyak AM, Reduced cholesterol transmucosal transport in rats with inhibited mucosal acyl CoA: cholesterol acyltransferase and normal pancreatic function. J Lipid Res 25: 148-159, 1984.
7. 7. Carr TP and Rudel LL, Partial inhibition of ACAT decreases apo B secretion by the liver of African green monkeys. Arteriosclerosis 10: 823A, 1990.
8. 8. Field FJ, Albright E and Mathur S, Inhibition of acyl CoA: cholesterol acyltransferase activity by PD 128042: effect on cholesterol metabolism and secretion in CaCo2 cells. Lipids 26: 1-8, 1991.
9. 9. Cianflone KM, Yasruel Z, Rodriguez MA, Vas D and Sniderman AD, Regulation of apoB secretion from HepG2 cells: evidence for a critical role of cholesteryl ester synthesis in the response to a fatty acid challenge. J Lipid Res 31: 2045-2055, 1990.
10. 10. Suckling KE and Stange EF, Role of acyl-CoA:cholesterol acyltransferase in cellular cholesterol metabolism. J Lipid Res 26: 647-671, 1985.
11. 11. Sliskovic DR and White AD, Therapeutic potential of ACAT inhibitors as lipid lowering and anti-atherosclerotic agents. TiPS 12: 194-199, 1991.
12. 12. Matsuda K, ACAT inhibitors as antiatherosclerotic agents: compounds and mechanisms. Med Res Rev 14: 271-305, 1994.
13. 13. Gallo LL, Bennett Clark S, Myers S and Vahouny GV, Cholesterol absorption in rat intestine: role of cholesterol esterase and acyl coenzyme A:cholesterol acyltransferase. J Lipid Res 25: 604-612, 1984.
14. 14. Krause BR, Anderson M, Bisgaier CL, Bocan T, Bousley R, DeHart P, Essenburg A, Hamelehle K, Homan R, Kieft K, McNally W, Stanfield R and Newton RS, In vivo evidence that the lipid-regulating activity of the ACAT inhibitor CI-976 in rats is due to inhibition of both intestinal and liver ACAT. J Lipid Res 34: 279-294, 1993.
15. 15. Krause BR, Pape ME, Kieft K, Auerbach B, Bisgaier CL, Homan R and Newton RS, ACAT inhibition decreases LDL cholesterol in rabbits fed a cholesterol-free diet: Marked changes in LDL cholesterol without changes in LDL receptor mRNA abundance. Arterioscler Thromb 14: 598-604, 1994.
16. 16. Harris NV, Smith C, Ashton MJ, Bridge AW, Bush RC, Coffee ECJ, Dron DI, Harper MF, Lythgoe DJ, Newton CG and Riddell D, Acyl-CoA:cholesterol O-acyl transferase (ACAT) inhibitors. 1. 2-(alkylthio)-4,5-diphenyl-1H-imidazoles as potent inhibitors of ACAT. J Med Chem 35: 4384-4392, 1992.
17. 17. Jones GD, Hoff TA, Gunraj PE, Facchini V and Chauhan PB, Assay and single dose pharmacokinetics of a novel systemic acyl coenzyme A:cholesterol O-acyltransferase inhibitor, RP 73163, in rat plasma, using automated solid-phase extraction with high performance liquid chromatography. J Chromatogr B 661: 119-131, 1994.
18. 18. Bello AA, Bridge AW, Bright C, Burton BJ, Bush RC, Casey J, Dron DI, Fachinni V, Joannou PP, Parrott DP, Riddell D, Roberts S and Williams RJ, RP 64477: An inhibitor of acyl-coenzyme A:cholesterol O-acyltransferase with low systemic bioavailability. Biochem Pharmacol 51: 413-421, 1996.
19. 19. Folch J, Lees M and Sloan-Stanley GH, A simple method for the isolation and purification of total lipides from animal tissue. J Biol Chem 226: 497-509, 1957.
20. 20. Lowry OH, Rosebrough NJ, Farr AL and Randall RJ, Protein measurement with the Folin phenol reagent. J Biol Chem 193: 265-275, 1951.
21. 21. Vahouny GV and Treadwell CR, Pancreatic sterol ester hydrolase. Methods Enzymol 15: 537-543, 1969.
22. 22. Stokke KT and Norum KR, Determination of lecithin:cholesterol acyltransferase in human blood plasma. Scand J Clin Lab Invest 27: 21-27, 1971.
23. 23. Havel RJ, Eder HA and Bragdon JH, The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J Clin Invest 34: 1345-1353, 1955.
24. 24. Hamilton JG and Comai K, Rapid separation of neutral lipids, free fatty acids and polar lipids using prepacked silica Sep-Pak columns. Lipids 23: 1146-1149, 1988.
25. 25. Otway S and Robinson DS, The use of a non-ionic detergent (Triton WR 1339) to determine rates of triglyceride entry into the circulation of the rat under different physiological conditions. J Physiol 190: 321-332, 1967.
26. 26. Egusa G, Brady DW, Grundy SM and Howard BV, Isopropanol precipitation method for the determination of apolipoprotein B specific activity and plasma concentrations during metabolic studies of very low density lipoprotein and low density lipoprotein apolipoprotein B. J Lipid Res 24: 1261-1267, 1983.
27. 27. Largis EE, Wang CH, DeVries VG and Schaffer SA, CL 277,082: a novel inhibitor of ACAT-catalysed cholesterol esterification and cholesterol absorption. J Lipid Res 30: 681-690, 1989.
28. 28. Chapman MJ. Comparative analysis of mammalian lipoproteins. Methods Enzymol 128: 70-143, 1986.
29. 29. Krause BR, Black A, Bousley R, Essenburg A, Cornicelli J, Holmes A, Homan R, Kieft K, Sekerke C, Shaw-Hes MK, Stanfield R, Trivedi B and Woolf T, Divergent pharmacologic activities of PD 132301-2 and CL 277082 urea inhibitors of acyl-CoA: cholesterol acyltransferase. J Pharm Exp Ther 267: 734-743, 1993.
30. 30. Bell FP, Gammill RB and St. John LC, U-73482: A novel ACAT inhibitor that elevates HDL-cholesterol, lowers plasma triglyceride and facilitates hepatic cholesterol mobilization in the rat. Atherosclerosis 92: 115-122, 1992.
31. 31. Cianflone K, Dahan S, Monge JC and Sniderman AD, Pathogenesis of carbohydrate-induced hypertriglyceridemia using HepG2 cells as a model system. Arterioscler Thromb 12: 271-277, 1992.
32. 32. Dashti N. The effect of low density lipoproteins, cholesterol, and 25-hydroxycholesterol on apolipoprotein B gene expression in HepG2 cells. J Biol Chem 267: 7160-7169, 1992.
33. 33. Khan B, Wilcox HG and Heimberg M, Cholesterol is required for secretion of very-low-density lipoprotein by rat liver. Biochem J 259: 807-816, 1989.
34. 34. Fungwe TV, Cagen L, Wilcox HG and Heimberg M, Regulation of hepatic secretion of very low density lipoprotein by dietary cholesterol. J Lipid Res 33: 179-191, 1992.
35. 35. Davis RA, Boogaerts JR, Borchardt RA, Malone-McNeal M and Archambault-Schexnayder J, Intrahepatic assembly of very low density lipoproteins: varied synthetic response of individual apolipoproteins to fasting. J Biol Chem 260: 14137-14144, 1985.
36. 36. Erickson SK, Shrewsbury MA, Brooks C and Meyer DJ, Rat liver acyl-coenzyme A: cholesterol acyltransferase: its regulation in vivo and some of its properties in vitro. J Lipid Res 21: 930-941, 1980.
37. 37. Quarfordt SH, Hanks J, Shelburne F and Schirmer B, Differing uptake of emulsion triglyceride by the fed and fasted rat liver. J Clin Invest 69: 1092-1098, 1981.
38. 38. Dixon JL and Ginsberg HN, Hepatic synthesis of lipoproteins and apolipoproteins. Sem Liver Dis 12: 364-372, 1992.
39. 39. Sehayek E, Friedman G and Eisenberg S, An apo-E (arginine 158) specific catabolic site in Hep-G2 cells. In: Atherosclerosis IX (Eds. Stein O, Eisenberg S and Stein Y), pp. 157-159. R&L Creative Communications, Tel Aviv, 1992.
40. 40. Kelley JL, Suenram CA, Rozek MM, Schaffer SA and Schwartz CJ, Influence of the acyl-CoA:cholesterol O-acyltransferase inhibitor, CL 277082, on cholesteryl ester accumulation in rabbit macrophage-rich granulomas and hepatic tissue. Biochim Biophys Acta 960: 83-90, 1988.
41. 41. Hrabek-Smith JM, Kurowska EM and Carroll KK, Effects of cholesterol-free, semipurified diets containing different levels of casein or soy protein on distribution of cholesterol and protein among serum lipoproteins of rabbits. Atherosclerosis 76: 125-130, 1989.
42. 42. Chao YS, Yamin TT, Seidenberg J and Kroon PA, Secretion of cholesteryl ester-rich lipoproteins by the perfused livers of rabbits fed a wheat-starch-casein diet. Biochim Biophys Acta 876: 392-398, 1986.
43. 43. Samman S, Khosla P and Carroll KK, Effects of dietary casein and soy protein on metabolism of radiolabelled low density apolipoprotein B in rabbits. Lipids 24: 169-172, 1989.